• Disc Medicine announced that it has now randomized and dosed the last participant in its pivotal, expanded 183-patient Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria and X-linked protoporphyria, with top-line data expected in the fourth quarter of 2026 and an FDA decision anticipated by mid-2027.
• The trial’s enlargement from 150 to 183 patients, driven by patient and physician demand, underlines meaningful engagement with a potential first disease-modifying therapy for these rare hematologic conditions.
• We’ll now examine how completing enrollment and dosing in the enlarged APOLLO Phase 3 trial shapes Disc Medicine’s investment narrative.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

What Is Disc Medicine's Investment Narrative?

To own Disc Medicine today, you have to believe that bitopertin can move from an investigational asset to a commercially relevant rare-disease franchise, and that the broader heme-modulation pipeline eventually follows. The latest APOLLO update, with the last patient now randomized and dosed in an expanded 183‑patient Phase 3 study, reinforces that the key near term catalyst remains the Q4 2026 readout and subsequent mid 2027 FDA decision after addressing the recent Complete Response Letter. Operationally, the enrollment milestone lowers execution risk around timelines, but does not change the binary nature of the program or the reality of rising losses, zero revenue, and a share price that has pulled back sharply year to date despite still trading well below some analyst fair value estimates. In my view, the investment case now hinges even more squarely on the quality of APOLLO data.

However, one risk investors should not overlook is what happens if APOLLO fails. Disc Medicine's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Two Simply Wall St Community fair value views stretch from about US$10 to roughly US$100, highlighting how differently people see Disc’s potential. Set that against rising losses, zero revenue, and a single pivotal trial now carrying most of the near term value debate.

Explore 2 other fair value estimates on Disc Medicine - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Disc Medicine research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Disc Medicine research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Disc Medicine's overall financial health at a glance.

Searching For A Fresh Perspective?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 62 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.